Core Insights - Microbix Biosystems Inc. will present to investors at the Muskoka Capital Event from September 26 to 28, 2025, focusing on growth-oriented investors [1][2] - The company aims to engage in 18 one-on-one meetings with investors during the event [2] - Microbix generates revenues targeting C$ 2.0 million or more per month and employs over 120 skilled employees [3] Company Overview - Microbix specializes in proprietary biological products for human health, particularly in the global diagnostics industry [3] - The company produces critical ingredients such as antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are sold in over 30 countries, supported by a network of international distributors [3] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [3] Product Development - Microbix develops proprietary products including Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [4] - The company’s QAPs and QUANTDx products support clinical lab accreditation and diagnostic workflows [3][4] Event Information - The Muskoka Capital Event is organized by Capital Event Management Ltd., featuring public and private companies and a range of investors [5] - The event aims to foster relationships that lead to financings and increased awareness within the investment community [5]
Microbix Presenting at Muskoka Capital Event